Quoin Pharmaceuticals Ltd ADR QNRX

$3.28 -0.08 (-2.35%)

Valuation

Market cap
15,758,000
Revenue TTM
$0
Net income TTM
$-15,800,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
11,300
Avg volume
29,158
Day's range
$3.18 – $3.64
Shares out
4,804,000
Stochastic %K
12%
Beta
1.71
Analysts
Strong Buy
Price target
$18.62

Price

Company profile

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It...

Show more

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

Industry
Biotechnology
Sector
Healthcare
Phone
703 980 4182
Website
https://quoinpharma.com
Address
42127 Pleasant Forest Court, Ashburn, United States

Latest news

Stocktwits

SqueezeSpecs Nov 12, 9:58 AM
$QNRX can explode from this base if they send some news out
0 replies
Ian_FV Nov 7, 12:04 AM
6-K/8-K Important Update $QNRX Quoin Pharmaceuticals Ltd. announced positive interim results from its Phase 2/3 study of QRX003 for Netherton Syndrome, meeting primary and key secondary endpoints. The company secured up to $50 million in private placement financing from healthcare-focused investors and received FDA clearance for its IND application for QRX003 in Peeling Skin Syndrome. Quoin also obtained FDA Rare Pediatric Disease and Fast Track Designations for PSS, along with Orphan Drug Designation from the European Medicines Agency. More details at www.ianfv.com
0 replies
MrTicker Nov 5, 1:34 PM
$QNRX Quoin Pharmaceuticals Q3 EPS $(0.97) Beats $(1.52) Estimate BENZINGA 7:31 AM ET 11/5/2026 Quoin Pharmaceuticals (QNRX) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.52) by 36.18 percent. This is a 85.54 percent increase over losses of $(6.71) per share from the same period last year.
0 replies
Ric_1M Nov 1, 12:16 PM
Happy November 🤍 $FMC $ASUR $NFE $QNRX $CLIK “Motivation gets you going, but discipline keeps you growing.” John C. Maxwell
0 replies
focafoca99 Oct 20, 10:46 AM
$QNRX unveiled a peer-reviewed paper on QRX003 showing dramatic skin improvement in a pediatric Netherton Syndrome case.
0 replies
notreload_ai Oct 19, 10:44 AM
Canaccord rates $QNRX and $MAZE Buy, with targets of $18 and $75. Quoin targets a rare skin disease with no approved treatment, while Maze’s kidney disease drug showed promising early results and may outperform a key competitor. https://notreload.xyz/wall-street-live-monday-october-19/
0 replies
mimiwor Oct 14, 10:46 AM
$QNRX no one cares but they have a news related with an orphan drug in europe....
0 replies
Johnnyshots Oct 14, 10:44 AM
$QNRX good news let's get it
0 replies